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Aims: The Questionnaire for Urinary Incontinence Diagnosis (QUID), a 6-item urinary incontinence (UI) symptom
questionnaire, was developed and validated to distinguish stress and urge UI. This study’s objective was to evaluate
QUID validity and responsiveness when used as a clinical trial outcome measure. Methods: Participants enrolled
in a multi-center trial of non-surgical therapy (continence pessary, pelvic floor muscle training or combined) for
stress-predominant UI and completed baseline and 3-month diaries, the Urinary Distress Inventory (UDI) and
QUID. Data from all treatment groups were pooled. QUID internal consistency (Cronbach’s a) and convergent/
discriminant validity (Pearson correlations) were evaluated. Responsiveness to change was assessed with 3-month
score outcomes and distribution-based measurements. Results: Four hundred forty-four women (mean age 50) were
enrolled with stress (N ¼ 200) and mixed (N ¼ 244) UI; 344 had 3-month data. Baseline QUID Stress and Urge
scores (both scaled 0–15, larger values indicating worse UI) were 8.4  3.2 and 4.5  3.3, respectively. Internal
consistency of QUID Total, Stress, and Urge scores was 0.75, 0.64 and 0.87, respectively. QUID Stress scores
correlated moderately with UDI-Stress scores (r ¼ 0.68, P < 0.0001) and diary stress UI episodes (r ¼ 0.41, P < 0.0001).
QUID Urge scores correlated moderately with UDI-Irritative scores (r ¼ 0.68, P < 0.0001) and diary urge UI episodes
(r ¼ 0.45, P < 0.0001). Three-month QUID Stress and Urge scores improved (4.1  3.4 and 2.2  2.7, both P < 0.0001).
QUID Stress score effect size (1.3) and standardized response mean (1.2) suggested a large change after therapy.
Conclusion: The QUID has acceptable psychometric characteristics and may be used as a UI outcome measure in
clinical trials. Neurourol. Urodynam. 29:726–733, 2010.  2010 Wiley-Liss, Inc.
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INTRODUCTION
Urinary incontinence (UI) occurs in approximately 16% of
adult women.1 The most common types of UI are stress
urinary incontinence (SUI), urge urinary incontinence (UUI) or
a combination of both (mixed UI). SUI is commonly treated
with pelvic floor exercises, pessaries, or surgery, while UUI is
commonly treated with behavior modification and/or drug
therapy, so it is important to accurately diagnose UI type.
Incontinence type is often diagnosed by history, with
confirmation by office evaluation or urodynamic testing;
however, history is often the most important contributor to
diagnosis.2 For this reason, UI symptom questionnaires are
valuable research and patient care instruments.
The Questionnaire for Urinary Incontinence Diagnosis
(QUID) is a self-administered, 6-item questionnaire designed
to distinguish between SUI and UUI.3 It was developed
through a rigorous process using literature review, review
by clinical and methodological experts and screening in
patients. The QUID is reliable and valid in diagnosing the
type of incontinence, when compared to standard clinical
evaluation in an outpatient urogynecology setting.3
Validation of a research instrument is ongoing process, and
the psychometric properties of any tool may differ in
populations with different disease prevalence and character-
istics. While the QUID has been shown to be a valid and
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reliable diagnostic tool for UI type, its value as an outcome
measure for treatment studies of UI has not been evaluated.
The Ambulatory Treatments for Leakage Associated with
Stress Incontinence (ATLAS) trial is a multi-center randomized
trial of non-surgical therapy for stress or stress-predominant
mixed UI.4 This study is well suited to further evaluate the
QUID’s psychometric characteristics. Our objective was to
assess the construct validity and responsiveness to change of
the QUID in women with stress and stress-predominant
mixed incontinence who undergo non-surgical therapy.
MATERIALS AND METHODS
Study Design and Participants
This was a prospectively planned ancillary analysis of the
ATLAS trial performed by the Pelvic Floor Disorders Network
(PFDN). All PFDN sites obtained local Institutional Review
Board approval and all participants completed informed
consent. Adult women with SUI and mixed (stress predom-
inant) UI were enrolled and randomized to treatment with a
continence pessary, behavioral therapy including pelvic floor
muscle training or combined therapy (continence pessary plus
behavioral therapy).4 Eligibility criteria included at least two
SUI episodes on a 7-day bladder diary and more SUI episodes
than other types of UI episodes recorded on the diary. Women
with continuous urinary leakage, current UI drug therapy,
stage III or IV pelvic organ prolapse,5 incomplete bladder
emptying or neurologic disorders associated with UI were
excluded.
Outcome Measures
Demographics, medical history, and physical examination
including Pelvic Organ Prolapse Quantification (POP-Q)5 were
completed on enrollment. At baseline and 3 months after
randomization, ATLAS participants completed self-adminis-
tered validated questionnaires including the QUID and a 7-day
bladder diary, on which they recorded numbers of voids and
UI leakage episodes by incontinence type (stress, urge, or
other). Participants were grouped by the presence or absence
of UUI episodes on the baseline bladder diary into mixed UI
(1 UUI episode recorded) and stress UI (no UUI episodes
recorded) groups.
The QUID (Appendix) identifies the presence and frequency
of stress and urge UI symptoms.3 Three items focus on stress
incontinence symptoms and three on urge incontinence
symptoms. Each item includes six frequency-based response
options, ranging from ‘‘none of the time’’ to ‘‘all of the time,’’
which are scored from 0 to 5 points. Scores are calculated in an
additive fashion, resulting in separate Stress and Urge scores,
each ranging from 0 to 15 points. Compared to a formal
clinical evaluation performed in urogynecology patients, use
of QUID scores (Stress scores 4 for SUI and Urge scores 6 for
UUI) identified UI type accurately in 80% of participants.3
UI-specific quality of life (QOL) instruments included the
Urinary Distress Inventory (UDI) and Urinary Impact Ques-
tionnaire (UIQ).6 Higher UDI and UIQ scale scores reflect
increasing symptom bother and greater impact on daily
activities from UI symptoms, respectively. UI severity was
assessed using the Incontinence Severity Index (ISI), a
validated 2-item questionnaire focusing on UI frequency and
volume. Responses to each item are multiplied to obtain a
severity score, which may be categorized as slight, moderate,
severe, and very severe.7
In addition to UI-specific questionnaires, sexual function
was characterized using the Pelvic Organ Prolapse-Urinary
Incontinence Sexual Function Questionnaire (PISQ-12)8 and
the Short Form Personal Experience Questionnaire (SPEQ).9
Higher scores for both reflect better sexual function. The
Medical Outcomes Study Short Form (SF-36) Mental Compo-
nent Summary (MCS) and Physical Component Summary (PCS)
scores10 and the Health Utility Index (HUI)11 were completed
to assess overall health-related QOL (SF-36) and health status
(HUI). Higher scores for each indicate better function.
Three months after randomization, participants also com-
pleted the Patient Global Impression of Improvement (PGI-I).12
This single item asks the participant to rate improvement of
her continence status using a 7-point response scale (1—very
much better, 2—much better, 3—a little bit better, 4—no
change, 5—a little bit worse, 6—much worse, and 7—very
much worse).
Statistical Analysis
Continuous variables were summarized by the mean,
standard deviation (SD), median, interquartile range (IQR)
and range. Categorical variables were summarized by counts
and percentages. At baseline, group characteristics and scores
were compared using the Fisher’s exact test or Chi-square test
(for categorical outcomes), the Wald test from an ordinal
logistic regression model (for ordinal outcomes) or the two-
sample Wilcoxon test (for continuous outcomes).
Convergent and discriminant validity were assessed by
calculating correlations (Pearson or Spearman) between base-
line QUID Total, Stress, and Urge scores and various diary and
questionnaire-based UI outcomes and other health-related
QOL measures. To determine the internal consistency of
baseline QUID Total, Stress, and Urge Scores, Cronbach’s a
statistic and 95% lower confidence bounds were calculated.13
We assessed construct validity by testing specific hypoth-
eses regarding the QUID Stress and Urge scores in the Stress
and Mixed UI groups, including (1) QUID Urge scores will be
higher in the ATLAS Mixed UI group than in the ATLAS Stress
UI group, and (2) QUID Stress scores will be greater than QUID
Urge scores in the ATLAS Mixed UI group. Paired t-tests were
used to compare these scores. In addition, we summarized the
proportion of participants with QUID Stress scores 4 in all
ATLAS subjects, and with QUID Urge scores 6 in the ATLAS
Mixed UI group. We expected that these proportions would be
high.
For the responsiveness to change analyses, the three
intervention groups were pooled as treatment assignment
remained blinded due to ongoing follow-up of study partic-
ipants. Changes from baseline to 3 months in the QUID and
other symptom and QOL measures were calculated (change
score ¼ 3-month score  baseline score). Pre-defined hypoth-
eses related to expected changes in the QUID scores after
treatment included: (1) QUID Stress scores will significantly
improve (scores decrease) from baseline to 3 months, (2) The
change in QUID Stress scale scores will be greater than that
seen in QUID Urge scale scores, and (3) QUID Total and QUID
Stress change scores will correlate with the PGI-I score.
Changes were analyzed with paired t-tests, Wilcoxon sign-
rank tests and the test described by Agresti14 (for the ISI).
Responsiveness was also assessed by calculating the QUID
effect size (ES) and standardized response mean (SRM). These
measures evaluate change in relation to sample variation,
providing a means of demonstrating that change has occurred
and of presenting that change in a standardized metric.15 The
ES was calculated as the change in mean score divided by the
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SD of the baseline score, and the SRM as the change in mean
score divided by the SD of the change.16
RESULTS
Four hundred forty-four women were enrolled in the ATLAS
trial, including 200 with SUI and 244 with mixed (stress-
predominant) UI. Patient characteristics and symptom and
QOL outcome measures at baseline are presented in Table I.
Overall, the mean  SD age was 50  12 years; 85% were
white. Eight percent had prior UI or prolapse surgery. The SUI
group was younger, more educated, more often pre-meno-
pausal and had lower body mass index (BMI) compared to the
mixed UI group. Women with mixed UI more often reported
hypertension than those with SUI (75 (31%) vs. 39 (20%),
P ¼ 0.009), but rates of other common medical problems did
not differ between the groups. Diary measurements indicate a
greater number of total leakage episodes, pads used, and voids
in the mixed UI group. Compared to the SUI patients, the
mixed UI group had greater QUID-Stress, Urge, and Total
scores, greater severity of UI, and greater symptom distress
and impact on daily living in all three PFDI and PFIQ scales.
The baseline individual QUID item responses and scores are
summarized for the Stress UI (Table IIA) and Mixed UI
(Table IIB) groups. Fewer than 1% of responses to each QUID
item were missing. The range of item responses was good for
all items and reflected the study inclusion/exclusion criteria
and the group definitions (stress vs. mixed UI). QUID item-
total correlations, a measurement of homogeneity within the
stress and urge item sets, were moderate for the Stress scale
and higher for the Urge scale.
QUID internal consistency at baseline was moderate to
good with Cronbach’s a (lower 95% confidence bound) of 0.75
(0.72) for QUID Total scores, 0.64 (0.59) for QUID Stress scores,
and 0.87 (0.85) for QUID Urge scores overall.
Table III displays baseline correlations between QUID
Stress, Urge, and Total scores with other UI symptom and
QOL measures to determine QUID convergent and discrim-
inant validity. QUID Stress scores correlated moderately with
UDI-Stress scores (r ¼ 0.68) and diary SUI episodes (r ¼ 0.41),
and, as expected, weakly with UDI-Irritative scores (r ¼ 0.28).
QUID Urge scores correlated moderately with UDI-Irritative
scores (r ¼ 0.68) and diary UUI episodes (r ¼ 0.45), and weakly
with UDI-Stress scores (r ¼ 0.29). QUID Urge scores had a weak
inverse correlation with SF-36 PCS and MCS scores (more urge
UI symptoms associated with poorer mental and physical
health-related QOL) (r ¼0.37 and 0.30, respectively), but
otherwise, QUID scores had non-significant or very weak
correlations with the sexual function and generic health
measures (Table III).
As presented in Table I, the mean QUID Urge score at
baseline in the mixed UI group was higher than in the SUI
group (5.9  3.1 compared with 2.8  2.8, P < 0.0001). Simi-
larly, QUID Stress scores were higher than QUID Urge scores in
the mixed UI group (8.9  3.2 vs. 5.9  3.1, P < 0.0001). A
substantial proportion (403, 93.3%) of women had QUID Stress
scores 4, including 176 (90.7%) in the stress UI group and 227
(95.4%) in the mixed UI group. One hundred thirty-four (56.3%)
of women in the mixed UI group had a QUID Urge score 6. By
comparison, 33 (16.9%) of women in the stress UI group had an
Urge score 6.
Three hundred sixteen subjects had complete data at
3 months and 344 women provided at least some 3-month
data, used to assess responsiveness to change. Changes in
QUID scores and other UI outcome measures are presented in
Table IV. All 3-month UI outcomes significantly improved,
including QUID Stress and Urge scores (decreased to 4.1  3.4
and 2.2  2.7, respectively; P < 0.0001 each), although QUID
Stress scores improved more than the QUID Urge scores
(difference 1.9  3.5, P < 0.0001). QUID Total, Stress, and Urge
change scores positively correlated with the PGI-I (more
negative symptom change scores associated with lower PGI-I
scores; both suggest improvement after treatment) (r ¼ 0.49,
0.47, and 0.34, respectively; P < 0.0001 for all). The QUID Stress
score ES was 1.3 and SRM was 1.2, suggesting a large change
after therapy compared to sample variation. QUID Urge and
QUID Total change scores’ ES were 0.7 and 1.2 with SRM of 0.8
and 1.2, respectively.
DISCUSSION
We evaluated the utility and psychometric properties of
the QUID when used as an outcome measure in an inter-
vention trial of women with SUI and stress-predominant
mixed UI undergoing non-surgical treatments for SUI. In this
setting, the QUID demonstrated acceptable internal consis-
tency, construct validity (including convergent/discriminant
validity) and responsiveness to change after therapy. These
data support the use of the QUID not only as a tool for
screening and diagnosing UI type, but also as a valid and
responsive measure of overall and type-specific UI symptom
frequency.
Questionnaires for UI can be divided into severity meas-
ures, condition-specific health-related QOL measures, and
diagnostic or screening questionnaires.17,18 The potential to
use the QUID as both a diagnostic tool and outcome measure
makes it relatively unique amongst available UI question-
naires, as most UI questionnaires are limited to one or the
other. The QUID was developed and validated to provide an
accurate diagnosis of UI type. The QUID correctly diagnosed UI
type in 80% of 117 women presenting for Urogynecologic care
and demonstrated a sensitivity and specificity for SUI (Stress
score 4) of 85% and 71% and for UUI (Urge score 6) of 79%
and 79%.3 A recent systematic review evaluating the most
accurate way to determine type of UI in an office setting
identified the QUID as one of the few available questionnaires
to aid in the diagnosis of SUI and UUI.18
The International Consultation on Incontinence Question-
naire—Urinary Incontinence Short Form (ICIQ-UI) is another
short questionnaire that provides a UI symptom severity score
as well as diagnostic information through a single non-scored
item in which subjects indicate when they leak (e.g., with
coughing and sneezing or on the way to the bathroom).19 In a
study comparing the ICIQ-UI diagnostic item to urodynamic
diagnoses, the ICIQ-UI’s sensitivities ranged from 0.48 to 0.70
and specificities ranged from 0.66 to 0.92 for UI diagnoses
(stress, urge, and mixed UI).20 Unlike the ICIQ-UI, the QUID
assesses frequencies of stress-specific and urge-specific UI
symptoms, therefore offering both clinicians and researchers
an easy, reliable method to quantify relative and absolute
change in frequency of stress and urge UI symptoms after
therapy.
A strength of the QUID is that it is relatively short with only
six items. As such, it may be less vulnerable to missing data
than longer questionnaires—in this study, fewer than 1% of
responses to QUID questions were missing. QUID internal
consistency differed slightly in this analysis from that
originally reported.3 When originally developed and validated,
QUID Stress and Urge scores demonstrated good internal
consistency with Cronbach’s a values of 0.85 and 0.87,
respectively. Internal consistency was slightly lower for the
Stress score in this population (0.64) for unclear reasons.
Neurourology and Urodynamics DOI 10.1002/nau
728 Bradley et al.
Neurourology and Urodynamics DOI 10.1002/nau
TABLE I. Baseline Characteristics and Symptom and QOL Measures in the Overall, Stress UI and Mixed UI Groups
Characteristic/measures Overall (n ¼ 444) Stress UI group (n ¼ 200) Mixed UI group (n ¼ 244) P-value*
Age (years) 49.7  11.9 47.2  11.3 51.8  12.0 <0.001
Race 0.800
White/Caucasian 378 (85.1) 169 (84.5) 209 (85.7)
Black/African-American 45 (10.1) 20 (10.0) 25 (10.3)
Asian 8 (1.8) 3 (1.5) 5 (2.1)
Other 13 (2.9) 8 (4.0) 5 (2.1)
Ethnicity 0.148
Hispanic 33 (7.4) 19 (9.5) 14 (5.7)
Non-Hispanic 411 (92.6) 181 (90.5) 230 (94.3)
Education 0.043
Less than high school 18 (4.05) 5 (2.5) 13 (5.3)
High school 83 (18.7) 32 (16.0) 51 (20.9)
Some college 146 (32.9) 65 (32.5) 81 (33.2)
4 years of college 107 (24.1) 54 (27.0) 53 (21.7)
Graduate/professional degree 90 (20.3) 44 (22.0) 46 (18.9)
Current smoker 51 (11.5) 21 (10.5) 30 (12.3) 0.654
Parity
# Cesarean deliveries 0.3  0.7 0.3  0.7 0.3  0.7 0.565
# Vaginal deliveries 2.0  1.5 1.9  1.2 2.1  1.7 0.425
Menopausal status <0.001
Pre 214 (48.2) 118 (59.0) 96 (39.3)
Post 187 (42.1) 60 (30.0) 127 (52.1)
Not sure 43 (9.7) 22 (11.0) 21 (8.6)
Prior hysterectomy 110 (24.8) 39 (19.5) 71 (29.1) 0.021
Prior prolapse/UI surgery 37 (8.4) 14 (7.0) 23 (9.4) 0.393
# Prescription meds 2.2  2.5 1.6  2.2 2.6  2.6 <0.001
BMI (kg/m2) 29.4  6.9 28.4  6.8 30.3  7.0 0.002
POP-Q stage 0.476
0 47 (10.6) 21 (10.5) 26 (10.7)
I 206 (46.5) 89 (44.5) 117 (48.2)
II 190 (42.9) 90 (45.0) 100 (41.2)
Diarya
UI episodes—stress 15.7  18.6 12.5  13.6 18.4  21.5 <0.001
UI episodes—urge 2.1  3.9 0.0  0.0c 3.8  4.6 <0.001
UI episodes—other 0.9  2.9 0.1  0.7 1.5  3.7 <0.001
UI episodes—total 18.7  22.0 12.5  13.7 23.8  25.9 <0.001
Pads—total 9.1  10.9 6.2  7.7 11.4  12.4 <0.001
Voids—total 62.5  18.8 59.8  17.8 64.7  19.3 0.003
QUID—Total (0–30) 12.9  5.3 10.5  4.7 14.8  5.0 <0.001
QUID-Stress (0–15) 8.4  3.2 7.7  3.2 8.9  3.2 <0.001
QUID-Urge (0–15) 4.5  3.3 2.8  2.8 5.9  3.1 <0.001
Incontinence Severity Index 0.001
Slight (1–2) 18 (4.2) 11 (5.7) 7 (3.0)
Moderate (3–6) 134 (31.3) 71 (36.6) 63 (26.9)
Severe (8–9) 239 (55.8) 103 (53.1) 136 (58.1)
Very severe (12) 37 (8.6) 9 (4.6) 28 (12.0)
UDI (0–300) 81.1  40.1 67.5  32.8 92.3  42.0 <0.001
UDI-Stress (0–100) 47.3  20.0 43.1  18.8 50.7  20.3 <0.001
UDI-Irritative (0–100) 19.6  15.8 13.8  12.7 24.4  16.6 <0.001
UDI-Obstructive (0–100) 14.3  15.3 10.6  12.4 17.3  16.8 <0.001
UIQ (0–400) 70.7  56.4 57.6  47.7 81.5  60.7 <0.001
PISQ-12 (0–48)b 34.2  5.86 35.4  5.51 33.1  5.98 0.001
SPEQ (3–15) 9.57  3.24 9.89  3.19 9.31  3.26 0.074
SF-36
Physical component 50.4  7.93 52.1  6.69 49.0  8.58 <0.001
Mental component 50.0  7.67 50.9  6.65 49.3  8.36 0.149
HUI 83.1  12.7 85.0  10.8 81.6  13.8 0.012
Data presented as mean  SD or n (%).
QOL, quality of life; UI, urinary incontinence; BMI, body mass index; POP-Q, Pelvic Organ Prolapse Quantification; QUID, Questionnaire for Urinary
Incontinence Diagnosis; UDI, Urinary Distress Inventory; UIQ, Urinary Impact Questionnaire; PISQ-12, Pelvic Organ Prolapse-Urinary Incontinence Sexual
Function Questionnaire (short-form); SPEQ, Short Form Personal Experience Questionnaire; SF-36, Medical Outcomes Study 36-item Short-Form Health
Survey; HUI, Health Utility Index.
*P-values for two-way comparison between Stress and Mixed UI groups.
aDiary variables all corrected to a 7-day total (variable total  7 /# valid days).
bThe PISQ-12 was completed by those women reporting sexual activity with a partner during the last 3 months (n ¼ 123 in the Stress UI group and n ¼ 132
in the Mixed UI group).
cBy definition, the Stress UI group had no Urge UI episodes recorded on the diary.
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TABLE II. Summary of QUID Item Responses and Scores at Baseline
QUID items Responses (n (%)) Item or Scale Score (mean  SD) Item-total correlation*
A. Stress UI group (N ¼ 200)
Item 1—cough/sneeze 3.5  1.1 0.30
All of the time (5) 37 (19.0)
Most of the time (4) 64 (32.8)
Often (3) 55 (28.2)
Once in awhile (2) 36 (18.5)
Rarely (1) 2 (1.0)
None of the time (0) 1 (0.5)
Item 2—bend down/lift up 1.6  1.4 0.54
All of the time (5) 3 (1.6)
Most of the time (4) 24 (12.4)
Often (3) 18 (9.3)
Once in awhile (2) 52 (26.8)
Rarely (1) 42 (21.7)
None of the time (0) 55 (28.4)
Item 3—walk/jog/exercise 2.7  1.7 0.42
All of the time (5) 37 (19.0)
Most of the time (4) 37 (19.0)
Often (3) 32 (16.4)
Once in awhile (2) 33 (16.9)
Rarely (1) 24 (12.3)
None of the time (0) 32 (16.4)
QUID Stress score — 7.7  3.2 —
Median (25th, 75th percentile) 8 (5, 10)
Range 1–15
Item 4—undressing for toilet 0.9  1.0 0.68
All of the time (5) 1 (0.5)
Most of the time (4) 1 (0.5)
Often (3) 13 (6.7)
Once in awhile (2) 36 (18.5)
Rarely (1) 53 (27.2)
None of the time (0) 91 (46.7)
Item 5—strong need to urinate 0.9  1.1 0.73
All of the time (5) 3 (1.5)
Most of the time (4) 3 (1.5)
Often (3) 9 (4.6)
Once in awhile (2) 35 (18.0)
Rarely (1) 53 (27.2)
None of the time (0) 92 (47.2)
Item 6—rush to bathroom 1.0  1.1 0.58
All of the time (5) 1 (0.5)
Most of the time (4) 8 (4.1)
Often (3) 12 (6.2)
Once in awhile (2) 35 (18.0)
Rarely (1) 54 (27.7)
None of the time (0) 85 (43.6)
QUID Urge score — 2.8  2.8 —
Median (25th, 75th percentile) 2 (0, 5)
Range 0–13
QUID Total score — 10.5  4.7 —
Median (25th, 75th percentile) 10 (7, 13)
Range 2–28
B. Mixed UI group (N ¼ 244)
Item 1—cough/sneeze 3.7  1.2 0.39
All of the time (5) 69 (29.0)
Most of the time (4) 73 (30.7)
Often (3) 54 (22.7)
Once in awhile (2) 35 (14.7)
Rarely (1) 3 (1.3)
None of the time (0) 4 (1.7)
Item 2—bend down/lift up 2.3  1.4 0.55
All of the time (5) 12 (5.0)
Most of the time (4) 35 (14.7)
Often (3) 60 (25.2)
Once in awhile (2) 69 (29.0)
Rarely (1) 32 (13.5)
None of the time (0) 30 (12.6)
Item 3—walk/jog/exercise 2.9  1.6 0.51
(Continued )
730 Bradley et al.
Internal consistency generally should be greater than 0.70.21
However, Cronbach’s a depends on the number of items as
well as the magnitude of correlations amongst items within a
scale. More items result in higher values for Cronbach’s a
(higher internal consistency).21 Thus for a 3-item scale like the
QUID-Stress, the internal consistency seen in this study is
adequate, particularly when balanced against the advantages
of a shorter questionnaire.
As we hypothesized, the QUID scales correlated with
appropriate measures of UI severity and symptom bother
including the bladder diary and UDI (convergent validity), but
less so with measures of sexual function and generic health
measures (discriminant validity). It is interesting that the
QUID correlated more strongly with the UDI (a measure of
symptom bother) than with the diary (a measure of symptom
frequency). This suggests that the ‘‘bother’’ rating in the UDI is
explained in large part by symptom frequency. Our results
may also indicate that the type of measure used (‘‘subjective’’
self-administered questionnaire vs. ‘‘objective’’ prospectively
recorded diary) influences responses to some extent. Similar to
our findings (moderate correlation between QUID scores and
diary results), past research shows the UDI also correlated
moderately with numbers of incontinence episodes reported
by bladder diary.6
Comparisons of the QUID Stress and Urge scores between
subjects in the stress and mixed UI groups were also
consistent with our a priori hypotheses, further supporting
the construct validity of the QUID. We did not anticipate
inverse correlations between the UUI frequency as measured
on the QUID-Urge scale and the mental and physical summary
scores of the SF-36. A similar relationship was not seen
with the QUID-Stress scale. This finding is consistent
with several studies that suggest health-related QOL is more
adversely affected by UUI than SUI.22,23 However, most
measures of UI severity and bother either do not correlate
or correlate only weakly with generic QOL measures like the
SF-36.24 Possibly, this difference is attributable to demo-
graphic and other differences between the Mixed and Stress
UI groups (e.g., older age, greater BMI, more prescription
medications).
Responsiveness to change, or the ability of an instrument to
detect change after treatment, is an essential psychometric
property for any scale intended to assess an intervention.21,24
Significant improvements in each of the QUID scales were
demonstrated after 3 months of non-surgical UI treatment.
These improvements correlated significantly with the
patient’s assessment of improvement (PGI-I). In addition, the
ES of the change was high for each QUID scale (0.7–1.3)
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TABLE II. (Continued)
QUID items Responses (n (%)) Item or Scale Score (mean  SD) Item-total correlation*
All of the time (5) 46 (19.3)
Most of the time (4) 51 (21.4)
Often (3) 52 (21.9)
Once in awhile (2) 41 (17.2)
Rarely (1) 25 (10.5)
None of the time (0) 23 (9.7)
QUID Stress score — 8.9  3.2 —
Median (25th, 75th percentile) 9 (7, 11)
Range 0–15
Item 4—undressing for toilet 1.9  1.1 0.68
All of the time (5) 3 (1.3)
Most of the time (4) 14 (5.9)
Often (3) 54 (22.7)
Once in awhile (2) 86 (36.1)
Rarely (1) 53 (22.3)
None of the time (0) 28 (11.8)
Item 5—strong need to urinate 2.0  1.1 0.78
All of the time (5) 4 (1.7)
Most of the time (4) 13 (5.5)
Often (3) 55 (23.1)
Once in awhile (2) 91 (38.2)
Rarely (1) 51 (21.4)
None of the time (0) 24 (10.1)
Item 6—rush to bathroom 2.0  1.3 0.65
All of the time (5) 10 (4.2)
Most of the time (4) 18 (7.6)
Often (3) 54 (22.7)
Once in awhile (2) 75 (31.5)
Rarely (1) 50 (21.0)
None of the time (0) 31 (13.0)
QUID Urge score — 5.9  3.1 —
Median (25th, 75th percentile) 6 (4, 8)
Range 0–15
QUID Total score — 14.8  5.0 —
Median (25th, 75th percentile) 15 (11, 18)
Range 2–30
UI, urinary incontinence; QUID, questionnaire for Urinary Incontinence Diagnosis; SD, standard deviation.
Items 1, 2, and 3 make up the QUID Stress scale, and items 4, 5, and 6 the QUID Urge scale.
*Pearson correlation between the individual item response and the corresponding total Stress or Urge score omitting that item; P < 0.0001 for all item-total
correlations.
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corresponding with good to excellent responsiveness.15,25 The
QUID responsiveness is similar to that of the ISI (ES ¼ 1.0) and
the UDI (ES ¼ .85) and greater than that of the number of UI
episodes on the bladder diary (ES ¼ .33). Thus, the QUID has
good to excellent responsiveness in women undergoing non-
surgical management for SUI or Stress predominant mixed
incontinence. As the treatment effect of surgery is typically
larger than that of non-surgical management, the responsive-
ness of the QUID to surgical treatment is expected to be even
larger than seen in this study.
The population of the ATLAS trial is larger and more
diverse in geographic location and UI severity than the
original study that described the QUID, expanding the
generalizability of this instrument. Other strengths of this
study include its prospective design, the use of multiple
validated outcome measures for comparison, and the use of
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TABLE IV. Changes in QUID Scores and Other UI Symptom and QOL Measures After Non-Surgical Stress UI
Therapy
Baseline (n ¼ 444) 3-month (n ¼ 344) Change* (n ¼ 344)
QUID—Total (0–30) 12.9  5.3 6.3  5.2 6.5  5.4
QUID—Stress (0–15) 8.4  3.2 4.1  3.4 4.2  3.6
QUID—Urge (0–15) 4.5  3.3 2.2  2.7 2.3  2.7
Diary UI episodes
Stress 15.7  18.6 4.4  11.4 9.8  17.3
Urge 2.1  3.9 0.8  2.7 1.3  3.8
Other 0.9  2.9 0.4  1.9 0.5  3.3
Total 18.7  22.0 5.5  12.6 11.7  21.0
ISI (n (%))
Dry (0) 0 (0.0%) 3 (0.9%) N/A
Slight (1–2) 18 (4.2) 146 (44.2%)
Moderate (3–6) 134 (31.3%) 107 (32.4%)
Severe (8–9) 239 (55.8%) 66 (20.0%)
Very severe (12) 37 (8.6%) 8 (2.4%)
UDI (0–300) 81.1  40.1 46.2  35.9 34.1  38.3
UDI-Stress (0–100) 47.3  20.0 27.6  20.8 19.2  22.3
UDI-Irritative (0–100) 19.6  15.8 10.5  12.0 8.7  13.9
UDI-Obstructive (0–100) 14.3  15.3 8.2  11.5 5.9  11.8
UIQ (0–100) 70.7  56.4 37.4  46.6 33.5  44.1
Data presented as mean  SD, unless otherwise indicated.
QUID, Questionnaire for Urinary Incontinence Diagnosis; UI, urinary incontinence; QOL, quality of life; ISI,
Incontinence Severity Index; UDI, Urinary Distress Inventory; UIQ, Urinary Impact Questionnaire
*Change scores ¼ 3-month scores  baseline scores; P-values (for within-group score changes) all <0.0001, except
P ¼ 0.008 for Diary UI episodes-Other.
TABLE III. Convergent/Discriminant Validity—Correlations Between Baseline QUID Stress, Urge, and Total
scores and Other UI Symptom and QOL Measures (n ¼ 444)
QUID—Stress scale (r*) QUID—Urge scale (r*) QUID—Total (r*)
Diarya
UI episodes—stress 0.41 0.27 0.42




UI episodes—total 0.41 0.34 0.46
UDI-Stress 0.68 0.29 0.59




UIQ 0.37 0.48 0.52
ISI 0.37 0.28 0.41
PISQ-12 0.12$ 0.26 0.23
SPEQ 0.05jj 0.22 0.17§
SF-36 PCS 0.10$ 0.37 0.29
SF-36 MCS 0.01jj 0.30 0.20
HUI 0.04jj 0.21 0.11$
QUID, Questionnaire for Urinary Incontinence Diagnosis; QOL, quality of life; UI, urinary incontinence; UDI,
Urinary Distress Inventory; UIQ, Urinary Impact Questionnaire; ISI, Incontinence Severity Index; PISQ-12, Pelvic
Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire-Short Form; SPEQ, Short Form Personal
Experience Questionnaire; HUI, Health Utility Index.
*Pearson correlations (except Spearman correlation for the ISI). P-values all <0.0001, unless otherwise indicated.
y
0.0001  P-value < 0.001.
§0.001  P-value < 0.01.
$0.01  P-value  0.05.
jjP-value >0.05.
aDiary variables all corrected to a 7-day total (variable total  7 /# valid days).
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well-described standardized treatments. A limitation is the
absence of patients with only UUI symptoms or urge-
predominant mixed UI. As such, these findings may only be
applicable to those with SUI or stress-predominant mixed UI.
However, the mixed UI group in this study did report
significant urge symptoms (average four UUI episodes
per week on diary) and the study findings support the validity
and responsiveness for the Urge scale in this population.
Moreover, QUID Urge scores showed convergent validity with
other validated urge measures including the UDI-Irritative
scale and the number of UUI episodes recorded on the bladder
diary. It seems unlikely that the QUID urge score would
perform less well in a population with only UUI than in a
population of patients with mixed UI as seen in this study.
CONCLUSIONS
The QUID is a short, valid, and responsive instrument that
can serve as a diagnostic tool to determine UI type and also as
a measure of stress and urge UI symptom frequency before
and after treatment. This versatility should prove useful to
both clinicians and researchers.
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Do you leak urine (even small drops), wet yourself, or wet your pads or undergarments . . .
1. When you cough or sneeze?
2. When you bend down or lift something up?
3. When you walk quickly, jog or exercise?
4. While you are undressing in order to use the toilet?
5. Do you get such a strong and uncomfortable need to urinate
that you leak urine (even small drops) or wet yourself before
reaching the toilet?
6. Do you have to rush to the bathroom because you get a sudden,
strong need to urinate?
Scoring: Each item scores 0 (None of the time), 1 (Rarely), 2 (Once in awhile), 3 (Often), 4 (Most of the time), or 5 (All of the time). Responses to items 1, 2, and
3 are summed for the Stress score; and responses to items 4, 5, and 6 are summed for the Urge score.
APPENDIX: THE QUESTIONNAIRE FOR FEMALE URINARY INCONTINENCE DIAGNOSIS (QUID)
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